1) *Kihara Y, Ikeda M, Takagi R, Ishigaki K, Yamanouchi K, Nagata S, Yamato M. Continuous adipose-derived stem cell therapy from the neonatal stage effectively reduces Duchenne muscular dystrophy symptoms in rats. Stem Cell Res Ther. 2025 Aug 26;16(1):452. doi: 10.1186/s13287- 025-04594-x.
2) *Ishigaki K, Takeuchi A, Taniguchi-Ikeda M, Sato T, Murakami T, Shichiji M, Ishiguro K, Kihara Y, Nagata S, Urade Y. Urinary prostaglandin D2 and E2 metabolites are elevated with disease severity in patients with Fukuyama congenital muscular dystrophy.Sci Rep. 2025 Feb 26;15(1):6873. doi: 10.1038/s41598-025-91539-2.
3) Murakami T, Sato T, Ishizuka T, Nakamura H, Tachimori H, Harada H, Oi H, Hatano K, Oba MS, Ishiguro K, Shichiji M, Kihara Y, Takeshima Y, Taniguchi-Ikeda M, Hattori A, Shimizu-Motohashi Y, Awano H, Bo R, Nagata S, * Ishigaki K. Nonrandomized Allocation of Steroid Therapy in Patients With Fukuyama Congenital Muscular Dystrophy: Study Protocol for a Phase II Clinical Trial. Neuropsychopharmacol Rep. 2025 Sep;45(3):e70043. doi: 10.1002/npr2.70043.
4) *Ishigaki K, Taniguchi-Ikeda M. Fukuyama congenital muscular dystrophy: Clinical features and therapeutic advances. Brain Dev. 2025 Sep 5;47(5):104437. doi: 10.1016/ j.braindev.2025.104437.
5) Yamamoto A, *Nagao M, Ishigaki K, Shichiji M, Kihara Y, Sakai A, Minami Y, Goto Y, Yoneyama M, Sakai S, Yamaguchi J.Myocardial injury in Duchenne muscular dystrophy: assessment via cardiac magnetic resonance intra-voxel incoherent motion. Heart Vessels. 2025 Jul 21. doi: 10.1007/s00380-025-02580-0.
6) *Ishigaki K, Taniguchi-Ikeda M. Fukuyama congenital muscular dystrophy: Clinical features and therapeutic advances. Brain Dev. 2025 Oct;47(5):104437.
7) Strober J, Ishigaki K, Posner N, Cappelleri JC, Xiao S, Talaga A, Dukacz S, Iqbal H, Chatterton E, Morton E, Weatherby S, *de Courcy J. Caregiver burden in Duchenne muscular dystrophy in Europe, Japan, and the United States – a real-world study. BMC Neurol. 2026 Jan 10;26(1):45 31- 8.
8) Ishiguro K, Kishi T, Sano K, Shichiji M, Sato T, Ishigaki K, *Nagata S. New onset of juvenile dermatomyositis after COVID-19 infection in two patients: a case report. Brain Dev Case Rep. 2026, 4(1), 100123.